Table 1

Descriptive data for the 17 qualifying trials

Source	Drug	Dose, mg	Duration, months	Participant treatment IHF	Placebo IHF	Mean age (range; years)	Region
Reid et al 22	Zoledronic acid	5 mg 18 monthly	72 months	8/1000	12/1000	71 (≥65)	European, Pacific, Asia
Black et al24	Zoledronic acid	5 mg yearly	24 months	52/3875	88/3861	73 (65–89)	Europe, America, Asia
Nakamura et al 20	Zoledronic acid	5 mg yearly	24 months	2/330	3/331	74 (65–89)	Japan
Bai26	Zoledronic acid	5 mg yearly	24 months	12/242	21/241	57	China
Ma	Zoledronic acid	5 mg yearly	36 months	8/327	13/333	55	China
Reginster27	Risedronate	5 mg daily	36 months	9/344	11/346	71	European, Pacific
Harris19	Risedronate	5 mg daily	36 months	12/812	15/815	69	North America
Mcclung18	Risedronate	2.5,5 mg daily	36 months	137/6197	95/3134	≥70	North America, Europe, Pacific
Recker et al 23	Ibandronate	0.5 mg, 1 mg, every 3 months	36 months	13/1912	11/950	67 (55–76)	USA, Europe
Harris19	Etidronate	400 mg daily, 2 weeks every 3 months	36 months	1/212	2/211	65	USA
Storm et al 16	Etidronate	400 mg daily, 2 weeks every 3 months	36 months	1/33	2/33	68 (56–75)	USA, Denmark
Liberman17	Alendronate	5 mg,10 mg, 20 mg daily	24 months	1/597	3/397	64 (45–80)	America, Pacific, Europe, Israel
Black25	Alendronate	5 mg daily 24 months, 10 mg daily 24–36 months	36 months	11/981	22/965	70 (55–81)	USA
Cummings et al 15	Alendronate	5 mg daily 24 months; 10 mg daily 24–36 months	36 months	19/2218	24/2214	67 (55–80)	USA
Greenspan et al 14	Alendronate	10 mg daily	24 months	2/163	4/164	79 (≥65)	USA
McCloskey et al 12	Clodronate	800 mg daily	36 months	1/292	6/301	67	UK
Brusmsen et al 13	Pamidronate	150 mg daily	36 months	1/51	1/50	65 (40–75)	Netherlands

IHF, incidence of hip fracture.